Infliximab Concentrations During Induction Are Predictive for Endoscopic Remission in Pediatric Patients With Inflammatory Bowel Disease Under Combination Therapy

To study infliximab (IFX) pharmacokinetics in children with inflammatory bowel disease (IBD) during induction therapy to predict outcome and explore if other covariates influenced outcome.

Source: The Journal of Pediatrics - September 2, 2021 Category: Pediatrics Authors: Karen van Hoeve, Nasim Sadat Seyed Tabib, Erwin Dreesen, Sophie Tops, Ilse Hoffman, Ann Gils, Marc Ferrante, S éverine Vermeire Tags: Original Articles Source Type: research